Amyris

Amyris, Inc. engages in the provision of bioscience solutions. It offers its products to the health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.

Earnings data Q1 2024

The principal business of Tara Gold Resources Corp. is the acquisition, exploration and development of high-quality precious metals projects with potential for economic commercial value. Tara Gold is currently focused on acquiring and developing properties in the natural resource belt of the Sierra Madre Occidental and other prolific areas in the states of Chihuahua, Sonora, and Sinaloa, Mexico.  Tara Gold provides investors growth exposure with a diversified exploration portfolio, multiple multi-million ounce targets and several near term production scenarios. Tara Gold owns equity positions in Cayden Resources Inc. (TSX-V: CYD) and Tara Minerals Corp. (TARM.OB), a public US company which explores and develops high-quality precious & non-precious metals and mineral projects in Mexico.

Proterra

WeWork

WeWork, a prized startup just four years ago but now a micro-cap, and other penny stocks such as Amyris and Proterra are the latest focus of speculative bets from retail traders, with shares of the financially struggling firms rising in strong trading volume after hitting record lows this week.

Retail investors flock to penny stocks WeWork, Amyris, Proterra

Amyris (NASDAQ: AMRS ) stock is rising higher on Friday with heavy trading after the biotechnology company filed for bankruptcy. AMRS stock is bouncing back after the company's stock took a beating on Thursday when it first announced its bankruptcy.

AMRS Stock Surges 152% as Amyris Files for Bankruptcy

Synthetic biotechnology company Amyris filed for Chapter 11 bankruptcy protection as it restructures, leading its share price to drop more than 70% in early trading Thursday.

Biotech Company Amyris Files for Bankruptcy

Amyris (NASDAQ: AMRS ) stock is falling on Thursday after the company filed for Chapter 11 bankruptcy protection. According to a press release from Amyris, the company is entering bankruptcy to facilitate a restructuring of its business.

Why Is Amyris (AMRS) Stock Down 67% Today?

Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif. , Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.

AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION

Cash-strapped specialty renewable products developer Amyris remains on life support by largest shareholder and creditor John Doerr. In recent months, Doerr has provided another $157.5 million in secured debt financing thus increasing his total secured debtholdings to $290 million with more likely to come. Last week, the company warned investors of a potential in-court restructuring as part of its ongoing restructuring efforts.

Amyris Warns Of Potential Bankruptcy - Sell

MannKind

Moderna

Novavax

Ocugen, Inc.

Cassava Sciences Inc

VBI Vaccines

Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category.

7 Biotech Stocks to Sell in July

The resignation of Amyris' CEO is likely to be viewed as a positive by many, but the implications of this are negative. Management turnover and the engagement of a consulting firm are not signs of a healthy business. Poor communication with shareholders also remains an issue. The company is reportedly trying to cut costs, but its efforts may not be as aggressive as necessary.

Amyris: CEO's Exit Has Negative Implications

Aeglea BioTherapeutics

Bionano Genomics

 Clene Nanomedicine

Clearmind Medicine Inc

Cybin

Hyzon Motors

IronNet

NeuroBo Pharmaceuticals Inc

Qurate Retail Inc

Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.

10 Top Penny Stocks To Watch Right Now For Under $1

Earlier this month, cash-strapped specialty renewable products developer Amyris announced a strategic transformation program to improve the company's cost and capital structure and liquidity. Secured debtholders agreed to amend the terms of existing credit facilities and waive existing defaults. The company also secured up to $50 million in additional loan commitments from Anesma Group LLC, an entity affiliated with director and largest shareholder John Doerr.

Amyris: Company Separates From Long-Standing CEO Amid Ongoing Restructuring Efforts - Sell

EMERYVILLE, Calif. , June 26, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately.

AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

SpringBig Holdings, Inc.

In the diverse financial market landscape, penny stocks hold a unique position. These low-priced shares, typically trading for less than $5 as defined by the U.S. Securities and Exchange Commission, usually belong to small companies that often go unnoticed by mainstream investors.

3 Penny Stocks Under $1 To Watch This Week; Time To Buy?

EMERYVILLE, Calif. , June 5, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced that its Board of Directors has engaged the Business Recovery Services unit of PricewaterhouseCoopers ("PwC") and established a subcommittee of the Board (the "Restructuring Committee"), made up of three independent directors, working with Management, to execute on a transformation program to accelerate improvements to the Company's cost and capital structure and liquidity.

AMYRIS INITIATES STRATEGIC TRANSFORMATION PROGRAM AND SECURES FUNDING

Eos Energy Enterprises

SciSparc Ltd

If there's one thing we know now it's that catalysts play a significant role in trading penny stocks. This is where things like sympathy sentiment can play a much larger role.

Hot Penny Stocks To Watch After UCAR Stock Explodes

Amyris (AMRS) sees lower sales in its Consumer and Technology Access segments in the first quarter.

Amyris (AMRS) Q1 Earnings In Line, Revenues Beat Estimates

EMERYVILLE, Calif. , May 19, 2023 Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, ("Croda") for the supply of sustainable squalene.

AMYRIS COMPLETES LICENSE FOR SUPPLY OF SUSTAINABLE SQUALENE

Amyris, Inc. (NASDAQ:AMRS ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants John Melo - President and CEO Han Kieftenbeld - CFO Eduardo Alvarez - COO Conference Call Participants Susan Anderson - Canaccord Genuity Korinne Wolfmeyer - Piper Sandler Colin Rusch - Oppenheimer Amit Dayal - H.C. Wainwright Rachel Vatnsdal - JP Morgan Chad Wiatrowski - TD Cowen Graham Tanaka - Tanaka Capital Management Operator Welcome to the Amyris First Quarter 2023 Financial Results Conference Call.

Amyris, Inc. (AMRS) Q1 2023 Earnings Call Transcript

Amyris, Inc. (AMRS) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago.

Amyris, Inc. (AMRS) Reports Q1 Loss, Tops Revenue Estimates

Core revenue of $56.1 million exceeded Q1 guidance of $49.9 million Cash operating expense down 4% compared to Q1 2022 and down 24% versus Q4 2022 Completed strategic partnership with Givaudan on April 3 for $200 million upfront cash EMERYVILLE, Calif. , May 9, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the first quarter ended March 31, 2023.

AMYRIS, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS

Amyris, Inc. (AMRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amyris, Inc. (AMRS) Expected to Beat Earnings Estimates: Should You Buy?

EMERYVILLE, Calif. , May 2, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets.

AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9

MP Materials

SunCoke Energy

TriMas

Valhi

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.

Top 5 Materials Stocks That May Explode In May - Amyris (NASDAQ:AMRS), MP Materials (NYSE:MP)

bluebird bio

LiveOne

Uniti Group

W&T Offshore

Analysts like these penny stocks but are they worth the risk?

5 Top Penny Stocks To Buy According To Analysts, Targets Up To 165%

Aclaris Therapeutics

Ionis Pharma

In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D.

3 Biotech Stocks to Sell Before They're 6 Feet Under

EMERYVILLE, Calif. , April 24, 2023 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, provided an update on first quarter revenue.

News for Amyris Stock (AMRS)